Safety, Pharmacokinetics and Pharmacodynamics of KT-621, an Oral STAT6 Degrader, in Healthy Adults
September 29, 2025
Safety, Pharmacokinetics and Pharmacodynamics of KT-621, an Oral STAT6 Degrader, in Healthy Adults
European Respiratory Society (ERS) 2025 Congress – Late Breaking Oral Presentation
Arsalan Shabbir, MD, PhD, Vice President, Clinical Development
Area of Focus
Immunology
Programs
STAT6 (KT-621)
Indications
Healthy Volunteers
Development Stage
Clinical Data
Share
